share_log

424B3: Prospectus

424B3: Prospectus

424B3：募資說明書
美股sec公告 ·  05/09 16:55
Moomoo AI 已提取核心訊息
eFFECTOR Therapeutics, Inc. has filed a prospectus supplement to update and amend information in its previous prospectus with new data from its Quarterly Report and Current Report. The supplement, filed on May 9, 2024, includes attached Quarterly and Current Reports and is essential for a complete understanding of the updated prospectus. eFFECTOR's common stock and warrants are listed on the Nasdaq under the symbols 'EFTR' and 'EFTRW,' with closing prices of $2.08 and $0.028 respectively as of May 8, 2024. The company, an emerging growth company, has not received approval or disapproval from the SEC or any state securities commission for these securities. The company's financial statements reveal a cash and cash equivalents balance of $15,508,000 as of March 31, 2024, and an accumulated deficit of $188,211,000. eFFECTOR...Show More
eFFECTOR Therapeutics, Inc. has filed a prospectus supplement to update and amend information in its previous prospectus with new data from its Quarterly Report and Current Report. The supplement, filed on May 9, 2024, includes attached Quarterly and Current Reports and is essential for a complete understanding of the updated prospectus. eFFECTOR's common stock and warrants are listed on the Nasdaq under the symbols 'EFTR' and 'EFTRW,' with closing prices of $2.08 and $0.028 respectively as of May 8, 2024. The company, an emerging growth company, has not received approval or disapproval from the SEC or any state securities commission for these securities. The company's financial statements reveal a cash and cash equivalents balance of $15,508,000 as of March 31, 2024, and an accumulated deficit of $188,211,000. eFFECTOR has experienced net losses and negative cash flows since inception, except for 2021 and 2020 due to a gain in fair value and revenue from a Pfizer agreement. The company's ability to continue as a going concern is dependent on additional capital, which may come from equity offerings, collaborations, licenses, or other arrangements.
Effector Therapeutics, Inc.已提交一份招股說明書補充文件，以使用其季度報告和當前報告中的新數據更新和修改其先前招股說明書中的信息。該補編於2024年5月9日提交，包括所附的季度和時事報告，對於全面了解更新的招股說明書至關重要。Effector的普通股和認股權證在納斯達克上市，代碼爲 “EFTR” 和 “EFTRW”，截至2024年5月8日，收盤價分別爲2.08美元和0.028美元。該公司是一家新興成長型公司，尚未獲得美國證券交易委員會或任何州證券委員會的批准或不批准這些證券。該公司的財務報表顯示，截至2024年3月31日，現金及現金等價物餘額爲15,508,000美元，累計赤字爲188,211,000美元。由於輝瑞協議的公允價值和收入的收益，除2021年和2020年外，Effector自成立以來一直經歷淨虧損和負現金流。公司繼續經營的能力取決於額外的資本，這些資本可能來自股票發行、合作、許可或其他安排。
Effector Therapeutics, Inc.已提交一份招股說明書補充文件，以使用其季度報告和當前報告中的新數據更新和修改其先前招股說明書中的信息。該補編於2024年5月9日提交，包括所附的季度和時事報告，對於全面了解更新的招股說明書至關重要。Effector的普通股和認股權證在納斯達克上市，代碼爲 “EFTR” 和 “EFTRW”，截至2024年5月8日，收盤價分別爲2.08美元和0.028美元。該公司是一家新興成長型公司，尚未獲得美國證券交易委員會或任何州證券委員會的批准或不批准這些證券。該公司的財務報表顯示，截至2024年3月31日，現金及現金等價物餘額爲15,508,000美元，累計赤字爲188,211,000美元。由於輝瑞協議的公允價值和收入的收益，除2021年和2020年外，Effector自成立以來一直經歷淨虧損和負現金流。公司繼續經營的能力取決於額外的資本，這些資本可能來自股票發行、合作、許可或其他安排。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息